This column was originally published on RealMoney on Dec. 2 at 10:49 a.m. EST. It's being republished as a bonus for readers.

The one area where speculation is alive and well is in the beat-up health care sector. Zimmer ( ZMH) up $4, Stryker ( SYK - Get Report) ramping, Boston Scientific ( BSX - Get Report) being rumored. Just perfect, a group with fundamentals that are so uncertain that the rumor mill's operating to get stockholders out of their bad positions.

I know I was tempted earlier this week to look at Stryker, given that it has had such huge insider buying. But I keep coming back to what happens when the government gets involved to hurt pricing.

I think that all of these stocks seem cheap, but I can't think of a catalyst. I debated Herb Greenberg last night on "Mad Money" about Merck ( MRK - Get Report) and Pfizer ( PFE - Get Report) and I know they look like "can't misses" with those yields and their long history of making you money.

But I keep coming back to rule one of my takeover trading tactics: Never speculate on takeovers with companies that have bad fundamentals. These have 'em; I am staying away.

James J. Cramer is a director and co-founder of He contributes daily market commentary for's sites and serves as an adviser to the company's CEO. Outside contributing columnists for and, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for ActionAlertsPLUS. Listen to Cramer's RealMoney Radio show on your computer; just click here. Watch Cramer on "Mad Money" at 6 p.m. ET weeknights on CNBC. Click here to order Cramer's latest book, "Real Money: Sane Investing in an Insane World," click here to get his second book, "You Got Screwed!" and click here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by clicking here.